ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 81 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,600,050 | -16.7% | 2,051,346 | -1.2% | 0.00% | – |
| Q2 2023 | $1,921,385 | -21.7% | 2,077,172 | -7.8% | 0.00% | – |
| Q1 2023 | $2,455,142 | -26.6% | 2,252,424 | -1.6% | 0.00% | – |
| Q4 2022 | $3,343,179 | +37.2% | 2,289,848 | +1.0% | 0.00% | – |
| Q3 2022 | $2,437,000 | -31.1% | 2,267,766 | +9.0% | 0.00% | – |
| Q2 2022 | $3,536,000 | -16.4% | 2,080,469 | +1.3% | 0.00% | -100.0% |
| Q1 2022 | $4,229,000 | -49.7% | 2,053,435 | -8.5% | 0.00% | 0.0% |
| Q4 2021 | $8,413,000 | +385.7% | 2,243,473 | +569.8% | 0.00% | – |
| Q3 2021 | $1,732,000 | -82.2% | 334,971 | -85.4% | 0.00% | -100.0% |
| Q2 2021 | $9,749,000 | -61.1% | 2,288,531 | -51.6% | 0.00% | -75.0% |
| Q1 2021 | $25,083,000 | -13.6% | 4,723,562 | -12.3% | 0.00% | 0.0% |
| Q4 2020 | $29,039,000 | +1132.6% | 5,387,488 | +1724.5% | 0.00% | – |
| Q3 2020 | $2,356,000 | +520.0% | 295,278 | +678.7% | 0.00% | – |
| Q2 2020 | $380,000 | +393.5% | 37,917 | +32.4% | 0.00% | – |
| Q1 2020 | $77,000 | +148.4% | 28,645 | +10.8% | 0.00% | – |
| Q4 2019 | $31,000 | -94.9% | 25,863 | -93.6% | 0.00% | – |
| Q3 2019 | $609,000 | -4.1% | 403,461 | +155.5% | 0.00% | – |
| Q2 2019 | $635,000 | -37.6% | 157,938 | -33.3% | 0.00% | – |
| Q1 2019 | $1,018,000 | +259.7% | 236,787 | +381.4% | 0.00% | – |
| Q4 2018 | $283,000 | +152.7% | 49,183 | +494.7% | 0.00% | – |
| Q3 2018 | $112,000 | -96.2% | 8,270 | -96.7% | 0.00% | -100.0% |
| Q2 2018 | $2,941,000 | +67.0% | 247,722 | +58.0% | 0.00% | – |
| Q1 2018 | $1,761,000 | +334.8% | 156,758 | +158.5% | 0.00% | – |
| Q4 2017 | $405,000 | +59.4% | 60,639 | +94.8% | 0.00% | – |
| Q3 2017 | $254,000 | +504.8% | 31,124 | +232.1% | 0.00% | – |
| Q2 2017 | $42,000 | -56.2% | 9,371 | -46.0% | 0.00% | – |
| Q1 2017 | $96,000 | +284.0% | 17,346 | +385.9% | 0.00% | – |
| Q3 2016 | $25,000 | -62.7% | 3,570 | -56.4% | 0.00% | – |
| Q2 2016 | $67,000 | -14.1% | 8,194 | -14.9% | 0.00% | – |
| Q1 2016 | $78,000 | +25.8% | 9,631 | +85.6% | 0.00% | – |
| Q4 2015 | $62,000 | +106.7% | 5,188 | +105.7% | 0.00% | – |
| Q3 2015 | $30,000 | -85.8% | 2,522 | -78.1% | 0.00% | – |
| Q2 2015 | $211,000 | – | 11,517 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $1,501,250 | 2.44% |
| NEA Management Company, LLC | 17,079,779 | $18,616,958 | 1.29% |
| Endurant Capital Management LP | 1,660,835 | $1,810,310 | 0.93% |
| Matrix Capital Management Company, LP | 38,974,185 | $42,481,862 | 0.58% |
| Long Focus Capital Management, LLC | 5,435,439 | $5,924,629 | 0.34% |
| PFM Health Sciences, LP | 5,992,571 | $6,531,902 | 0.29% |
| Key Client Fiduciary Advisors, LLC | 321,155 | $350,059 | 0.22% |
| DAFNA Capital Management LLC | 351,064 | $382,660 | 0.12% |
| Rock Springs Capital Management LP | 2,787,845 | $3,038,751 | 0.07% |
| Baker Brothers Advisors | 9,830,877 | $10,715,656 | 0.06% |